November 11, 2020 07:57 AM EST
FDA+

Ex­pect­ed mis­takes, the need for speed, and change to come: CBER's Pe­ter Marks looks ahead

Kari Oakes

In a wide-rang­ing Nov. 6 dis­cus­sion with the pres­i­dent and CEO of the Friends of Can­cer Re­search, Jeff Allen, CBER di­rec­tor Marks spoke to tem­per­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times